Lung Cancer Trials Ask AI to find trials
RecruitingPhase 4NCT03340506
Official study title

Dabrafenib and/or Trametinib Rollover Study

Study summary

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studieddabrafenib and trametinib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 22, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 4

Interventional

Where is it offered?38 U.S. locations

Locations may change over time.

Who runs it?Novartis Pharmaceuticals

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 4
Sponsor
Novartis Pharmaceuticals
Interventions being studied
Drug: dabrafenib; Drug: trametinib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
  • In the opinion of the Investigator would benefit from continued treatment.
Reasons someone may not be able to joinExclusion criteria
  • Patient has been previously permanently discontinued from study treatment in the parent protocol.
  • Patient's indication is commercially available and reimbursed in the local country.
  • Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Honor Health Research InstituteScottsdale, Arizona
  • National Institute Of HealthBethesda, Maryland
  • James Cancer Hospital and Solove Research Institute Ohio StateColumbus, Ohio
  • Mary Crowley Cancer ResearchDallas, Texas
  • Novartis Investigative SiteCaba, Buenos Aires
  • Novartis Investigative SiteInnsbruck, Tyrol
  • Novartis Investigative SiteToronto, Ontario
  • Novartis Investigative SiteBeijing
  • Novartis Investigative SiteBrno
  • Novartis Investigative SitePrague
  • Novartis Investigative SiteCopenhagen
  • Novartis Investigative SiteLyon

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 22, 2026. Always confirm current availability with the study team.

View original record ↗